Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

Safe Orthopaedics : Announces Its Revenues for The 1st Half of 2019 and the Commercial Launch of SteriSpine PS Gen 2

07/10/2019 | 12:31pm EDT

► Strong sales growth of +32% in the 2nd quarter of 2019

► Half-year revenues up +21% to € 2,041k

► Commercial launch of SteriSpine PS Gen 2

► First surgeries using SteriSpine Gen 2 scheduled as of July 2019

► A 2019 growth rate set to outstrip that of 2018

Regulatory News:

Safe Orthopaedics (Paris:SAFOR) (FR0012452746 - SAFOR), a company specializing in the design and marketing of single-use implants and instruments for the minimally invasive treatment of spinal fracture conditions, is today announcing its half-year revenues for the six months ended June 30, 2019.

“Safe Orthopaedics is closing the first half of 2019 with accelerated growth in the second quarter that is up +32% (+16% in the first quarter) on 2018, thanks to the promotion of our strategic SteriSpine PS (pedicle screw combined with its ready-to-use sterile instrumentation) and SteriSpine VA (vertebral augmentation balloon launched at the end of 2018) ranges for fracture treatment, the return to growth among our distributors and our Japanese partnership,” comments Pierre Dumouchel, Managing Director and co-founder of Safe Orthopaedics. “The intensive training undergone by the many sales representatives recruited since the beginning of the year in France, Germany and the United Kingdom, along with preparations for the launch of the second-generation SteriSpine PS have been important milestones in the first half of the year. Thanks to the know-how of our engineers and the feedback from our surgeons after more than ten thousand surgeries performed with SteriSpine PS since its first CE marking in 2011, we are proud to offer this new generation: thinner, more resistant, and still radio-transparent, it allows the surgeon to perform an increasingly minimally invasive surgical approach.”

In thousands of euros

Q1 19

Q2 19

H1 2019

Q1 18

Q2 18

H1 2018


Q2 19/Q2 18


H1 19/H1 18

Direct sales (FR, DE, UK)










Indirect sales










Total revenues










Sales posted by the French team amounted to € 851k, driven by the growth of the 5 sales representatives already active in 2018 and the strategic SteriSpine PS and VA ranges. The German and British teams generated € 153k in sales, boosted by the SteriSpine PS range.

The replacement/recruitment of 4 French sales representatives, as well as the doubling of the German and British sales teams in the first quarter, as previously announced by the company, combined with the commercial launch of the new generation of the SteriSpine PS range, are the growth drivers for the second half of the year.

In the Rest of the World, sales increased by +46%, mainly due to the Japanese commercial partnership. Only the SteriSpine PS range is currently distributed there, although the registration and launches of the other ranges are scheduled for the second half of the year.

Internationally, sales generated by other distributors amounted to € 572k, with a return to positive growth of 7% in the second quarter.

Commercial launch of SteriSpine PS Gen 2

Internationally, the strategic PS and VA ranges needed to treat the fracture, the core of the company's strategy, posted accelerated growth in the second quarter of 29%, and 21% in the first quarter.

The company is announcing the commercial launch of the second generation of SteriSpine PS as of July 2019. Thanks to the company's accumulated know-how in the design and industrialization of unique and internationally patented polymer instruments, this second generation of SteriSpine PS is thinner, more resistant, and still radio-transparent, allowing the surgeon to perform an increasingly minimally invasive surgical approach.

Cash position

As at June 30, 2019, Safe Orthopaedics' cash position amounted to € 1.1 million, compared with € 500k at the end of June 2018. As a reminder the general meeting of June 7, 2019 approved a € 12.15 million financing line covering cash requirements until 2022, the prospectus of which is currently being reviewed by the French Financial Markets Authority.

Next financial publication

Results for the first half of 2019, on September 27th (after market close)

About Safe Orthopaedics

Founded in 2010, Safe Orthopaedics, is a French medical technology company that offers the safest technologies to treat spinal fractures. Delivered sterile, all implants and respective disposable instrumentation are available to the surgeon at any time, anywhere. These technologies enable minimally invasive approaches, redcucing risks of cross contamination and infection in the interest of the patient. Protected by 17 patent families, SteriSpineTM kits are CE marked and FDA cleared. The company is based in Eragny-sur-Oise (95) and has 50 employees.

For more information: www.SafeOrthopaedics.com

ę Business Wire 2019
Latest news "Companies"
05:59pLUCID : to start deliveries of electric cars with range exceeding Tesla's in October
05:58pFIRM CAPITAL PROPERTY TRUST : Announces the Acquisition of a 40% Interest in a Core Toronto Retail Property With an Institutional Partner for $23.8 Million
05:58pNabis Holdings Announces the Results of Its Annual and Special Shareholder Meeting
05:58pNabis Holdings Announces the Results of Its Annual and Special Shareholder Meeting
05:58pEAGLE MOUNTAIN MINING LIMITED (ASX : EM2) 500m Mineralisation Strike Potential at Western Talon
05:55pN.Korea tests new hypersonic missile as it ramps up weapon systems
05:55pPFIZER : vaccine for kids may not be available until November
05:52pVINCO VENTURES : rsquo; Subsidiary Emmersive Entertainment Announces World Renown Artist Super Buddha's Forthcoming E-NFT entitled “Global Unity”
05:52pAFYA : Sustainalytics ESG Risk Rating is Publicly Available
05:46pSun Communities, Inc. Prices $600 Million of Senior Notes
Latest news "Companies"